CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006
October 26 2006 - 6:00PM
PR Newswire (US)
PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) announced that data from three
ranolazine-related studies will be presented at the American Heart
Association (AHA) Scientific Sessions 2006, which will be held at
McCormick Place in Chicago, IL, on November 12 - 15, 2006. The
presentations are: -- Evidence that the antianginal agent,
ranolazine, improves post-ischemic stunned myocardium in the
rabbit. Monday, November 13, 2006 from 11:30 a.m. to 11:45 a.m.
Oral abstract #2171. -- Exercise capacity on treadmill test
predicts future cardiac events. Monday, November 13, 2006 from 2:30
p.m. to 2:45 p.m. Oral abstract #2600. -- Effects of ranolazine as
monotherapy and combination therapy on rate pressure product at
rest and during exercise: Results from the MARISA and CARISA
trials. Wednesday, November 15, 2006 from 11:30 a.m. to 11:45 a.m.
Oral abstract #3362. Additional information regarding the AHA
Scientific Sessions 2006 can be accessed at
http://scientificsessions.org/ . About CV Therapeutics CV
Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved product, Ranexa(R) (ranolazine
extended-release tablets) is indicated for the treatment of chronic
angina in patients who have not achieved an adequate response with
other antianginal drugs, and should be used in combination with
amlodipine, beta-blockers or nitrates. CV Therapeutics also has
other clinical and preclinical drug development candidates and
programs, including regadenoson, which is being developed for
potential use as a pharmacologic stress agent in myocardial
perfusion imaging studies and CVT-6883, which is being developed as
a potential treatment for asthma and other conditions. Regadenoson
and CVT-6883 have not been determined by any regulatory authorities
to be safe or effective in humans for any use. DATASOURCE: CV
Therapeutics, Inc. CONTACT: John Bluth, Senior Director, Corporate
Communications and Investor Relations, of CV Therapeutics, Inc.,
+1-650-384-8850 Web site: http://www.cvt.com/
http://scientificsessions.org/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024